Why this measure won
There is no agreed way to describe weight loss after bariatric surgery, where an older measure, percent excess weight loss, is also used. A 2016 study of 2,420 people after gastric bypass compared the two. They started at an average BMI of 46.8. After one year they had lost on average 30.0% of total body weight, 68.5% of excess weight, and their BMI had fallen by 14.1 points on average. The excess-weight figure depended strongly on how heavy people were at the start, a correlation of −0.52 with starting BMI, while total weight loss did not, 0.04. The authors concluded that total weight loss should be the measure of choice. They counted under 20% at 12 months as a suboptimal result, which applied to 11.3% of patients.3
What the trials report
- Zepbound, SURMOUNT-1: 15.0%, 19.5% and 20.9% on 5, 10 and 15 mg over 72 weeks, against 3.1% on placebo.2
- Wegovy, STEP 1: 14.9% over 68 weeks, against 2.4% on placebo.1
- Orforglipron, ATTAIN-1: 11.2% over 72 weeks on the highest dose, against 2.1% on placebo.4
- Saxenda, adults without diabetes: 7.4% over 56 weeks, against 3.0% on placebo.5
- Qsymia: 10.9% in a year on the top dose, against 1.6% on placebo.6
- Contrave, COR-I: 5.4% over 56 weeks, against 1.3% on placebo.7
People started at similar weights: 104.8 kg on average in SURMOUNT-1, 106.2 kg in the Saxenda trial and about 115 to 119 kg in the Qsymia trials.2,5,6 Still, these are averages from different trials, with different lengths and people, so they are not a ranking.
The 5%, 10% and 15% marks
Trials also report the share of people who passed set levels of TBWL, usually 5%, 10% and 15% of starting weight. In STEP 1, 5% or more was reached by 86.4% on semaglutide against 31.5% on placebo, 10% or more by 69.1% against 12.0%, and 15% or more by 50.5% against 4.9%.1 The Saxenda label turns one of these marks into a rule. Weight is checked 16 weeks after starting, and Saxenda is stopped if the person has not lost at least 4% of their starting weight, since a meaningful loss is then unlikely with more treatment.5
The older medicines show the same pattern at lower levels. On Saxenda, in adults without diabetes, at least 5% was lost by 62.3% against 34.4% on placebo, and more than 10% by 33.9% against 15.4%.5 On Contrave in COR-I, at least 5% was lost by 42% against 17%, and at least 10% by 21% against 7%.7 On Qsymia, at least 10% was lost by 47% on the top dose, 19% on the lowest dose and 7% on placebo.6 These shares say more than the average does, because they show how many people reached each level.
Working out your own number
Because TBWL is a share of the starting weight, the starting weight has to be recorded on day one. The same 22 lb is 10% for someone who started at 220 lb and about 7% for someone who started at 300 lb, which is why the percentage, not the pounds, is what compares with trial results.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. Funded by Novo Nordisk; NCT03548935. doi:10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. NCT04184622. doi:10.1056/NEJMoa2206038
- Corcelles R, Boules M, Froylich D, et al. Total weight loss as the outcome measure of choice after Roux-en-Y gastric bypass. Obes Surg 2016;26:1794-1798. doi:10.1007/s11695-015-2022-y
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. Funded by Eli Lilly. doi:10.1056/NEJMoa2511774
- SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published June 15, 2026; boxed warning, recent major changes and sections 1, 2, 6.1, 11, 12 and 14. dailymed.nlm.nih.gov
- QSYMIA (phentermine and topiramate extended-release capsules) prescribing information. Vivus LLC; DailyMed, U.S. National Library of Medicine, version published April 24, 2026; sections 1, 2, 4, 5, 6.1, 8.1 and 14. dailymed.nlm.nih.gov
- CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets prescribing information. DailyMed, U.S. National Library of Medicine, version published November 17, 2025; boxed warning and sections 1, 2, 4, 5, 6.1, 7.2 and 14. dailymed.nlm.nih.gov
Related analyses
Zepbound plateau: when weight loss slows, why, and what the trials show
Why people stop GLP-1 medications: how many quit, why, and how many come back
Muscle loss on Zepbound and Wegovy: how much of the weight lost is fat, and how much is muscle
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
Log your starting weight once, and the app shows your total weight loss as a percentage.
Open Dose Insider